Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...
Sangamo Therapeutics
Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand
Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...
Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB
Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...
Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered...
Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study
Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the...